Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death.
about
On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosisEpstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation.Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells.Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expressionEpstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo.NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1Virally targeted therapies for EBV-associated malignancies.Epstein-Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression.Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expressionCytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferationEpstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma.Identification of a negative regulatory element in the Epstein-Barr virus Zta transactivation domain that is regulated by the cell cycle control factors c-Myc and E2F1.Inhibition of germinal centre apoptotic programmes by epstein-barr virus.Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes.Interaction of EBV latent origin of replication with the nuclear matrix: identification of S/MAR sequences and protein components.Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication.The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells.EBV Persistence--Introducing the Virus.Epstein-Barr virus BZLF1 protein impairs accumulation of host DNA damage proteins at damage sites in response to DNA damage.Promoter sequences required for reactivation of Epstein-Barr virus from latencyInhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds.Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression.Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer.Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication.Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes.Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer.Epstein-Barr virus antagonizes the antiproliferative activity of transforming growth factor-beta but does not abolish its signaling.CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy.Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.EBV and Apoptosis: The Viral Master Regulator of Cell Fate?
P2860
Q24645207-A827997D-95E4-424E-8717-397B7CFEB379Q33843334-4CC13E8D-880F-495A-B468-322387CC421DQ33851707-E485CA59-8E24-4A32-B7AA-A111AB1DE8D3Q34103135-269CB9E9-9BAC-41A6-AD08-6198F40BA951Q34301695-08647322-6570-4C38-9988-578AAAF6DDA0Q34350013-DF044A87-3CE4-4FE7-84FB-CC8F1A360EF5Q34465924-E2DCE71B-F0BE-4DA0-8B14-35C785569475Q34532370-57F9F8BA-7BCB-4C86-9895-45C803509028Q34553645-13BD8347-8A88-4E49-A3B4-805FCA418FE8Q35077613-7928AB0E-D9C6-452E-84F2-7AF23641EE55Q35196601-6F4B61BC-3A11-47BF-A7F9-56B44007B43CQ35476446-6C4EA7AE-ED15-4AD8-9769-99114B0F7294Q36804608-8E19F165-299D-4A0D-B977-E98008059C3BQ36890569-D2757A4B-7E56-4E4A-96CA-691EAC8436C7Q37449248-56D7855F-B0A6-4B1E-858F-931D6AE657C7Q37583477-06FF8A80-36E9-4E6A-AC27-1CB27C30D20FQ37959963-4AC7962D-45F6-4564-949B-6D38D852C9B9Q38309488-B53A7080-38DD-4F0D-B7BA-04060B089095Q38352558-3CB55DCC-E9CF-477B-B7DD-6A3D28848769Q38359264-BEDEC09D-B384-40D3-BC5A-084E645E26EFQ38360833-9CBFBD86-4FD1-4DC9-B9C4-A796946BF359Q38596344-DE3DAE52-B8C1-4260-80FF-37CA9C2561BBQ38871275-2944EFBE-4202-4E9C-85A1-03DD2CD1DED3Q39685040-1C1D8D80-CBE4-4571-8B6A-95847F18C028Q39875400-1F0E880E-AD40-487C-811A-A3CB84295186Q40069082-4E5B618E-C40E-4322-A32D-414E6C3E3757Q40075775-14E36334-71BB-4429-8503-180FDC4EB2C1Q40102087-85877523-F12E-438C-9E1E-4E3264EB85A5Q40137307-A6D7096C-9E79-4882-8CFA-3F2D7650D863Q40178497-8172CDB6-DBDD-44CF-B114-B93D4578CDE1Q40207035-4771E06C-D578-436F-925A-AF326267996CQ40221184-6321E779-4D74-4B38-9759-9B2E00C3D423Q40560316-475A2DAB-26FF-4694-BA55-9C7FDD7E8006Q40608955-44AC2CEC-AF7F-4F57-88A1-C785060C2B80Q40705838-F1A9A5D4-1C98-4381-A442-09094F402D51Q42282904-5739E09F-CE85-4A4B-8216-09D9800FFE72Q42376067-C837ED27-82EC-4A57-B87B-6C22F7559A76Q45324906-0B229DB1-EA5D-4F06-93ED-8EDF28180571Q45360289-81D28774-87D5-435F-AD0C-68E7661669A1Q47117102-C6CE4F9C-7536-4EE8-A651-1FFFA66BED50
P2860
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Activators of the Epstein-Barr ...... sion protects from cell death.
@en
Activators of the Epstein-Barr ...... sion protects from cell death.
@nl
type
label
Activators of the Epstein-Barr ...... sion protects from cell death.
@en
Activators of the Epstein-Barr ...... sion protects from cell death.
@nl
prefLabel
Activators of the Epstein-Barr ...... sion protects from cell death.
@en
Activators of the Epstein-Barr ...... sion protects from cell death.
@nl
P2093
P2860
P1433
P1476
Activators of the Epstein-Barr ...... sion protects from cell death.
@en
P2093
P2860
P304
P356
10.1128/JVI.75.5.2400-2410.2001
P407
P577
2001-03-01T00:00:00Z